ClinicalTrials.gg
RecruitingNCT03549416BioDayUpdated Mar 28, 2025

BioDay Registry: Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Dermatitis

An observational study in Atopic Dermatitis, sponsored by UMC Utrecht. Recruiting at 14 sites in Netherlands. Open to participants aged 0 Years and older. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by UMC Utrecht · Observational

From the registry’s dates

  • Started Jan 2018; still recruiting 8 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,200
Ages
0 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies in Dermatitis, Atopic with a site in Netherlands — 7 open to participants now, 14 under way, 3 of them phase 3. Dermatitis, Atopic · Netherlands.

Planned enrollment
3rd of 13
1,200 · median 500
Started
2018
with 10 others
Observational
13 of 73
5 open now
Primary completion
2028-12
later than 8 of 13 live
Registered
30th of 73
by date
Lead sponsor
4 of 73
UMC Utrecht

Among the 73 studies in Dermatitis, Atopic with a site in Netherlands, this one is the 3rd largest by planned enrollment of the 13 observational ones that give a count, is one of 11 that started in 2018, is one of 13 observational ones, reaches primary completion later than 8 of the 13 other live ones, and was the 30th registered.

Dermatitis, Atopic

1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

7 of the 73 studies in Dermatitis, Atopic with a site in Netherlands are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 0 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Dermatitis, Atopic with a site in Netherlands, or all of them as a file.
02

Study summary

The BioDay Registry aims to address the need for daily practice data regarding the effectiveness and safety of new systemic treatment options (like biologics and Janus kinase inhibitors) in patients with atopic dermatitis and effect on other atopic comorbidities in a multicenter setting. The registry already consists of several additional modules concerning atopic comorbidities, like food allergy and asthma, and a module for conjunctivitis during biologic treatment.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Atopic dermatitis
  • Dupilumab
  • Dupixent
  • BioDay
  • Daily practice
  • Real world
  • Atopic Diseases Registry
  • Registry
  • Multi center
  • Biologics
  • Janus kinase inhibitors
  • Baricitinib
  • Upadacitinib
  • Abrocitinib
  • Tralokinumab
04

Who can participate

Ages eligible
0 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry

Exclusion criteria

Exclusion Criteria:

  • Patients are not eligible for enrolment in case of presumed inability to answer questionnaires or not willing to answer questionnaires and will be excluded.
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,200 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

This study also gives Dupilumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Assessment of effectiveness

    To assess the effectiveness of new treatments in adult and pediatric patients with AD using physician measured clinical eczema scores as well as patient-reported outcome measures.

    Time frame: Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)

  2. Drug survival

    To study drug survival and identify factors that affect drug survival.

    Time frame: Drug survival analysis, which is the length of time a patient continues to take a particular drug, will be performed every year, with cumulative results over the years.

  3. Side effects

    To register objective and subjective side effects and to identify potential risk factors.

    Time frame: Change from baseline to previous specified timepoints (16 weeks, 1 year, 2 year etc.)

Secondary outcomes

  1. Characterization of population

    To characterize patient populations treated with new AD treatments in daily practice.

    Time frame: Yearly from baseline up to 5 years

  2. Characterization of side effects

    To collect data from daily practice regarding side effects (incidence, severity, risk factors, treatment options, etc.).

    Time frame: Yearly from baseline up to 5 years

  3. Laboratory monitoring

    To study the usefulness of laboratory monitoring during treatment in daily practice, with emphasis on subpopulations (e.g. elderly patients, patients with pre-existing liver and/or renal disease).

    Time frame: Yearly from baseline up to 5 years

  4. Long-term safety

    To study the long-term safety risks including malignancies, pregnancy/paternity-related conditions, infections, and autoimmune diseases.

    Time frame: Yearly from baseline up to 5 years

  5. Comorbidities

    To prospectively collect data from daily practice regarding the effect of new treatment options for AD on comorbidities (for example atopic diseases like asthma, food allergy and rhinoconjunctivitis can improve from these new drugs as many target the Th2 axis).

    Time frame: Yearly from baseline up to 5 years

  6. Dose tapering

    To assess whether dose reduction of biologics can be achieved in patients with low AD activity.

    Time frame: Yearly from baseline up to 5 years

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2028, 131 months after the start.

Of 97 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 131 months is above that.

Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 17.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2018
First posted
Jun 8, 2018
StartActual
Jan 1, 2018
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03549416
Lead sponsor
UMC Utrecht
Collaborators
Academisch Ziekenhuis Groningen, Sanofi, AbbVie, Eli Lilly and Company, LEO Pharma
Responsible party
Dr M.S. de Bruin-Weller (M.S. de Bruin-Weller, dermatologist, MD, PhD, UMC Utrecht) — Principal investigator
First posted
Jun 8, 2018
Start date
Jan 1, 2018
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Mar 28, 2025

Study contacts

Marlies de Graaf, MD, PhD
Contact
M.deGraaf-10@umcutrecht.nl
+31887571134
Ilona de Ridder
Contact
L.H.deRidder-2@umcutrecht.nl
Marjolein de Bruin-Weller, Md, PhD
principal investigator · UMC Utrecht

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion